Back to search results

L-Theanine for Relaxation and Mood in Cancer Patients

This study is testing L-theanine, a substance found in green tea, to see if it can help cancer patients in surveillance (after treatment) with relaxation and mood. Researchers want to find the best dose and see how well it works. L-theanine may help by increasing certain body chemicals linked to stress reduction and better mood. You may be able to join if you are 18 or older, can read English or Spanish, and are willing to take L-theanine and complete follow-up assessments. The study will look at how well people stick to taking L-theanine and how it affects their perceived relaxation levels over about six weeks.

Study design
This interventional study plans to enroll 50 participants who will be randomly assigned to receive L-theanine once or twice daily.
What's involved
You would take L-theanine by mouth daily for 6 weeks and complete questionnaires.
Compensation
Not stated in the trial record.
Follow-up
Your perceived relaxation levels will be measured from the beginning of the study up to day 42.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07220447

L-Theanine to Support Relaxation and Mood for Cancer Patients in Surveillance

Recruiting
EARLY_PHASE1Ages 18+InterventionalSupportive care
City of Hope Medical Center
~50 participants
Updated 2026-05-08 on ClinicalTrials.gov
What's tested:Survey AdministrationTheanine

At a glance

Recruiting sites
1 of 4 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Adherence rates
Measured over Up to 8 weeks
+1 more outcome measured

Conditions

Hematopoietic and Lymphatic System Neoplasm
Malignant Solid Neoplasm

Explore related trials

Hematopoietic and Lymphatic System NeoplasmSolid Neoplasm

NCT07220447

Where you'd take part

This study runs at 4 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • City of Hope at Irvine Lennar

    Irvine, Californiastudy coordinator listed

    Not yet recruiting

  • City of Hope at Irvine Sand Canyon

    Irvine, Californiastudy coordinator listed

    Not yet recruiting

  • City of Hope Medical Center

    Duarte, Californiastudy coordinator listed

    Recruiting

  • City of Hope Seacliff

    Huntington Beach, Californiastudy coordinator listed

    Not yet recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Erica Veguilla · PRINCIPAL_INVESTIGATOR · City of Hope Medical Center

Who to contact

Erica Veguilla
[email protected]
949-671-4673
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Documented informed consent of the participant and/or legally authorized representative.
Assent, when appropriate, will be obtained per institutional guidelines
Willingness to comply with all study interventions including the use of L-theanine and follow-up assessments
Age: ≥ 18 years
Ability to read and understand English or Spanish for questionnaires
Patients must be a cancer patient who has completed treatment and has been in surveillance for at least 6 months
Participants must not have used any herbs or supplements in the past 30 days
Participants must report an anxiety score of \> 3 on Visual Analog Scale - Anxiety
Participants must not have had any changes to their psychiatric medications within the past 60 days
Women of childbearing potential (WOCBP): negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 1 month after the last dose of protocol therapy.
Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for \> 1 year (women only)

Exclusion

Concurrent use of other alternative medicines, including herbal agents and high-dose vitamins and minerals, unless taken to correct a documented vitamin or mineral insufficiency
Chemotherapy, radiation therapy, biological therapy, immunotherapy, or any other systemic treatment excluding hormonal therapy (must be on a stable dose of hormonal therapy for at least 60 days)
Any patients taking bortezomib, as L-theanine can decrease effectiveness
Any patients currently enrolled in other clinical trials that might interfere with the results of this study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent
Any patients with an ongoing active/unstable psychiatric condition, depressive/bi-polar related disorders, anxiety, psychosis disorders, or substance use that may interfere with the ability to participate in the study as outlined in the study procedures section of the protocol
Any patients with chronically unstable blood pressure or chronic low blood pressure
Diagnosis of Gilbert's disease
Females only: Pregnant or breastfeeding
Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures
Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)

What this trial measures

  • Adherence ratesUp to 8 weeks

    Will consider the study feasible if at least 75% of enrolled participants adhere to the planned intervention. Adherence will be defined as having at least 75% study drug accountability. Will be estimated along with the 95% exact binomial confidence interval.

  • Perceived levels of relaxationFrom baseline to day 42

    Measured via Visual Analog Scale-Relaxation (VAS-R). Response is defined as a favorable change of at least 1.5 points on the VAS-R. Will be estimated along with the 95% exact binomial confidence interval. Within-group mean changes in VAS-R will be examined using paired t-tests (comparing any two time points of interest).